Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer

被引：0
|
作者：
Gyorffy, Balazs
Santarpia, Libero
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-03-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-03-07
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Androgen receptor-positive, triple-negative breast cancer
    Gucalp, Ayca
    Traina, Tiffany A.
    CANCER, 2017, 123 (10) : 1686 - 1688
  • [22] What's positive about 'triple-negative' breast cancer?
    Hurvitz, Sara A.
    Finn, Richard S.
    FUTURE ONCOLOGY, 2009, 5 (07) : 1015 - 1025
  • [23] Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Hongshu Li
    Ying Chang
    Tiefeng Jin
    Meihua Zhang
    Cancer Cell International, 25 (1)
  • [24] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [25] Anti-PD-L1 for metastatic triple-negative breast cancer
    Gibson, Josefine
    LANCET ONCOLOGY, 2015, 16 (06): : E264 - E264
  • [26] PD1, PD-L1 and PD-L2 mRNA Expression in triple-negative Breast Cancer
    Schueler, K.
    Bethmann, D.
    Staege, M.
    Kantelhardt, J. E.
    Thomssen, C.
    Vetter, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : E24 - E24
  • [27] PD-L1-positive cancer stem cells in primary tumour associated with progression of breast cancer
    Vtorushin, S.
    Kalinchuk, A.
    Popova, N.
    Tashireva, L.
    VIRCHOWS ARCHIV, 2024, 485 : S209 - S209
  • [28] Indian triple-negative breast cancer - immune, molecular and clinical landscape
    Sadanandam, A.
    Korlimarla, A.
    Ragulan, C.
    Prabhu, J.
    Shankaranarayana, H.
    Cheang, M.
    Sridhar, T. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
    Gregorio, Ana C.
    Lacerda, Manuela
    Figueiredo, Paulo
    Simoes, Sergio
    Dias, Sergio
    Moreira, Joao Nuno
    PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (04) : 701 - 716
  • [30] Immune Tolerance to FVIII is mediated by PD-L1-positive Tregs Comment
    Figueiredo, Constanca
    TRANSFUSIONSMEDIZIN, 2023, 13 (02) : 71 - 71
12345